Legend Biotech Corporation
LEGN
$32.80
-$0.66-1.97%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | 186.30M | 159.92M | 184.10M | 90.66M | 79.42M |
Total Other Revenue | 224.00K | 281.00K | 2.42M | 3.33M | 41.00K |
Total Revenue | 186.52M | 160.21M | 186.52M | 93.99M | 79.46M |
Cost of Revenue | 178.35M | 150.99M | 163.08M | 155.70M | 138.13M |
Gross Profit | 8.17M | 9.21M | 23.45M | -61.71M | -58.67M |
SG&A Expenses | 83.13M | 79.57M | 65.42M | 56.15M | 62.38M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 261.48M | 230.56M | 228.49M | 211.86M | 200.52M |
Operating Income | -74.96M | -70.36M | -41.97M | -117.86M | -121.05M |
Income Before Tax | 40.51M | -120.89M | -17.97M | -59.79M | -146.81M |
Income Tax Expenses | 14.23M | 4.44M | 226.00K | 5.00K | -1.99M |
Earnings from Continuing Operations | 26.28M | -125.32M | -18.20M | -59.79M | -144.82M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 26.28M | -125.32M | -18.20M | -59.79M | -144.82M |
EBIT | -74.96M | -70.36M | -41.97M | -117.86M | -121.05M |
EBITDA | -72.06M | -67.98M | -39.19M | -115.07M | -118.30M |
EPS Basic | 0.29 | -1.37 | -0.20 | -0.66 | -1.59 |
Normalized Basic EPS | 0.15 | -0.41 | -0.06 | -0.21 | -0.50 |
EPS Diluted | 0.29 | -1.37 | -0.20 | -0.66 | -1.60 |
Normalized Diluted EPS | 0.14 | -0.41 | -0.06 | -0.21 | -0.50 |
Average Basic Shares Outstanding | 183.32M | 183.28M | 182.60M | 182.01M | 181.83M |
Average Diluted Shares Outstanding | 100.70M | 91.64M | 91.30M | 91.00M | 90.91M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |